VANCOUVER, British Columbia--(BUSINESS WIRE)--InNexus Biotechnology, Inc. (TSX VENTURE:IXS) (OTCBB:IXSBF), an innovative antibody-driven drug development company, today announced that it has entered into an R&D agreement with BioInvent International AB, a publicly-traded biotech firm, for the provision of InNexus’ SuperAntibody™ Technology with a BioInvent therapeutic antibody, targeting cancer. Under the agreement the Parties will perform collaborative R&D aimed at a single target. The agreement also contains terms for future drug development including commercialization. Financial terms of the transaction were not disclosed.
